Alerta De Seguridad para Vascular Graft Prosthesis: (1) Distaflo Bypass, (2) Flexible with Small Bubble. Catalog No. (1) DF5006SC, DF5007SC, DF6006SC, DF6007SC, DF7006SC, DF8006SC; (2) F1006TWS, F3006TWSC, F310086TWS, F310086TWSC, F5006S, F5006SC, F5006TWS, F5006TWSC, F5008S, F5008TWS, F5008TWSC, F6006TWS, F6006TWSC, F7004TWS, F7005TWS, F7005TWSC, F7006S, F7006SC, F7006TWS, F7006TWSC, F7007TWS, F7007TWSC, F7008S, F7008SC , F7008TWS, F7008TWS, F7008TWS, F70N75TSC, F70N75TWS, F70T74TSC, F70T74TWS, F70T85TWS, F70T85TWS, F8006S, F8006SC, F8006TWS, F8007TWS, F8007TWS, F8007TWSC, F8008S, F8008SC, F8008TWS, F8008TWSC

Según Agência Nacional de Vigilância Sanitária (ANVISA), este evento ( alerta de seguridad ) involucró a un dispositivo médico en Brazil que fue producido por IMPRA Inc Div C R Bard Inc.

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Safety alert
  • ID del evento
    242
  • Fecha
    2000-12-29
  • País del evento
  • Fuente del evento
    ANVISA
  • URL de la fuente del evento
  • Notas / Alertas
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Notas adicionales en la data
    UNTIL THIS DATE DOES NOT CONSERT PRODUCT REGISTRATION IN BRAZIL
  • Causa
    The uk has demanded of impra to provide better instructions for use of the aforementioned prostheses to alert doctors in removing the small bubble and also demanded of impra withdrawing the product from the market to remedy the problem. the manufacturer initiated the recall of the defective product outside the united states by mail dated may 1999 and august 2000.
  • Acción
    Make sure that you have received the dated May 1999 and August 2000 correspondence from Impra. Identify and isolate any affected product from your inventory. ECRI recommends that you inform if any of the above units have been deployed in your institution and by whom. Tell the implant surgeon that the product is subject to removal. It is up to the cardiac surgeon to decide on the need for medical intervention in patients who have been implanted with the product. No action is necessary in the United States. For removal instructions, contact your local representative or directly with Impra at (1) (480) 894-9515 in the United States. ANVISA recommends that your establishment ensure that all patients who have these products in place are followed periodically and that this follow-up is documented in order to protect their implantable physicians and their establishment from a legal point of view. If it is necessary to replace the implants, if there is any difficulty in recovering from the manufacturer, immediately contact the ANVISA Technovigilance for arrangements.

Manufacturer

  • Source
    ANVSANVISA